Oxford Nanopore
Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments â MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
CEO: Gordon Sanghera
Website: www.nanoporetech.com
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
PacBio and Oxford Nanopore sequencers perform well on "easy" genes that have traditionally been sequenced on Illumina machines, as well as on intractable genes.
Oxford Nanopore Technologies Expects 2022 Revenue to Rise 49 Percent
The company expects 2022 revenue to be approximately £199.0 million, including around £147.0 million in life science research tools revenue.
Customers are feeling euphoric, but sequencing firms face a number of headaches including competitive pressure and global macroeconomic concerns.
Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay
The project will leverage Asuragen's long-range PCR and Oxford Nanopore's sequencing capabilities to develop a sequencing workflow for carrier screening.
SMS-seq combines structural probing with direct RNA nanopore sequencing, offering researchers a new way to study RNA structure at the single-molecule level.